Role of thalidomide in previously untreated patients with multiple myeloma

References

• Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood111, 3968–3977 (2008).
   PubMed Web of Science ®Google Scholar
• Kastritis E, Dimopoulos MA. Thalidomide in the treatment of multiple myeloma. Best Pract. Res. Clin. Haematol.20, 681–699 (2007).
   PubMed Web of Science ®Google Scholar
• Glasmacher A, Hahn C, Hoffmann F et al. A systematic review of Phase II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br. J. Hematol.132, 584–593 (2006).
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol.121, 749–757 (2003).
   PubMed Web of Science ®Google Scholar
• Kyle RA, Remstein ED, Therneau TM et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med.356, 2582–2590 (2007).
   PubMed Web of Science ®Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol.21, 16–19 (2003).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Gertz MA, Lacy MQ et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia17, 775–779 (2003).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol.20, 3419–3423 (2002).
   Google Scholar
• Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica89, 826–831 (2004).
   PubMed Web of Science ®Google Scholar
• Abdelkefi A, Torjman L, Ben Romdhane N et al. First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma. Bone Marrow Transplant.36, 193–198 (2005).
   PubMed Web of Science ®Google Scholar
• Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood106(1), 35–39 (2005).
   PubMed Web of Science ®Google Scholar
• Cavo M, Terragna C, Testoni N et al. Incorporation of thalidomide into up-front double autologous stem-cell transplantation (ASCT) for newly diagnosed multiple fails to overcome the poor prognosis imparted by chromosome 13 deletion. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12–15 2008. Haematologica93(Suppl. 1) (2008) (Abstract 206).
   Google Scholar
• Vogl DT, Liu SV, Chong EA et al. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support. Am. J. Hematol.82, 1071–1075 (2007).
   PubMedGoogle Scholar
• Dingli D, Rajkumar SV, Nowakowski GS et al. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a Phase II trial. Haematologica90, 1650–1654 (2005).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.24, 431–436 (2006).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Rosiñol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J. Clin. Oncol.26, 2171–2177 (2008).
   PubMed Web of Science ®Google Scholar
• Macro M, Divine M, Uzunhan Y et al. Dexamethasone+thalidomide (dex/thal) compared with VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): a randomized trial. Presented at: 48th American Society of Hematology Annual Meeting. FL, USA, 9–12 December 2006. Blood108 (2006) (Abstract 57).
   Google Scholar
• Ludwig H, Tothova E, Hajek R et al. Thalidomide–dexamethasone vs. melphalan–prednisone as first line treatment and thalidomide–interferon vs. interferon maintenance therapy in elderly patients with multiple myeloma. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8–11 December 2007. Blood110, (2007) (Abstract 529).
   Google Scholar
• Musto P, D’Auria F. Melphalan: old and new uses of a still master drug for multiple myeloma. Expert Opin. Invest. Drugs25, 4459–4465 (2007).
   Google Scholar
• Palumbo A, Bertola A, Musto P et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer104, 1428–1433 (2005).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Caravita T et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet367, 825–831 (2006).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Liberati AM et al. Oral melphalan, prednisone and thalidomide in elderly patients with multiple myeloma: updated results of a randomised controlled trial. Blood25(28), 4459–4465 (2008).
   Google Scholar
• Facon T, Mary J, Hulin C et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet370, 1209–1218 (2007).
   PubMed Web of Science ®Google Scholar
• Hulin C, Facon T, Rodon P et al. Melphalan–prednisone–thalidomide (MP-T) demonstrates a significant survival advantage in elderly patients >75 years with multiple myeloma compared with melphalan and prednisone (MP) in a randomized, double blind, placebo-controlled trial IFM 01–01. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8–11 December 2007. Blood110 (2007) (Abstract 75).
   Google Scholar
• Gulbrandsen N, Waage A, Gimsing P et al. A randomised placebo-contolled study with melphalan/prednisone vs melphaln/prednisone-thalidomide: quality of life and toxicity. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12–15 2008. Haematologica93(Suppl. 1) (2008) (Abstract 209).
   Google Scholar
• Wijermans P, Schaafsma M, Van Norden Y et al. Melphalan + prednisone vs melphaln + prednisone + thalidomide in induction therapy for multiple myeloma in elderly patients: first interim result of the Dutch cooperative group HOVON. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12–15 2008. Haematologica93(Suppl. 1) (2008) (Abstract 440).
   PubMedGoogle Scholar
• Dimopoulos MA, Anagnostopoulos A, Terpos E et al. Primary treatment with pulsed melphalan, dexamethasone and thalidomide for elderly symptomatic patients with multiple myeloma. Haematologica91, 252–254 (2006).
   PubMed Web of Science ®Google Scholar
• Breitkreutz I, Lokhorst HM, Raab MS et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia21, 1294–1299 (2007).
   PubMed Web of Science ®Google Scholar
• Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica93, 124–127 (2008).
   PubMed Web of Science ®Google Scholar
• Offidani M, Corvatta L, Piersantelli MN et al. Thalidomide, dexamethasone and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myeloma. Blood108, 2159–2164 (2006).
   PubMed Web of Science ®Google Scholar
• Zervas K, Dimopoulus MA, Hatzicharissi E et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol.15, 134–138 (2004).
   PubMed Web of Science ®Google Scholar
• Hussein MA, Baz R, Srkalovic G et al. Phase II study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed/refractory multiple myeloma. Mayo Clin. Proc.81, 889–895 (2006).
   PubMed Web of Science ®Google Scholar
• Zervas K, Mihou D, Katodritou E et al. VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek myeloma study group. Ann. Oncol.18, 1369–1375 (2007).
   PubMed Web of Science ®Google Scholar
• Hassoun H, Reich L, Klimek VM et al. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective and well tolerated initial therapy for multiple myeloma. Br. J. Haematol.132, 155–161 (2006).
   PubMed Web of Science ®Google Scholar
• Wu P, Davies FE, Horton C et al. The combination of cyclophosphamide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide–vincristine–doxorubicin–methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. Leuk. Lymphoma47, 2335–2338 (2006).
   PubMed Web of Science ®Google Scholar
• Jagannath S, Bensinger B, Vescio R et al. A Phase II study of bortezomib (Velcade®), cylophosphamide (Cytoxan®), thalidomide (Thalomid®) and dexamethasone as first-line therapy for multiple myeloma. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8–11 December 2007. Blood110 (2007) (Abstract 188).
   Google Scholar
• Barlogie B, Tricot G, Anaissie E et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N. Engl. J. Med.354, 1021–1030 (2006).
   PubMed Web of Science ®Google Scholar
• Zangari M, van Rhee F, Anaissie E et al. Eight-year median survival in multiple myeloma after Total Therapy 2: roles of thalidomide and consolidation chemotherapy in the context of Total Therapy 1. Br. J. Haematol.141(4), 433–444 (2008).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Pineda-Roman M, van Rhee F et al. Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood (2008) (Epub ahead of print).
   Google Scholar
• Cavo M, Patriarca F, Tacchetti P et al. Bortezomib (Velcade®)–thalidomide–dexamethasone (VTD) vs thalidomide–dexamethasone (TD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Presented at: 49th American Society of Hematology Annual Meeting. Atlanta, USA, 8–11 December 2007. Blood110 (2007) (Abstract 73).
   Google Scholar
• Hicks LK, Haynes AE, Reece DE et al. A meta-analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat. Rev.34(5), 444–452 (2008).
   Google Scholar
• Moreau P, Hulin C, Facon T. Frontline treatment of multiple myeloma in elderly patients. Blood Rev. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Palumbo A, Rajkumar SV, Dimopoulos MA et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia22, 414–423 (2008).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Cavo M, Bringhen S et al. Enoxaparin versus aspirin versus low-fixed-dose of warfarin in newly diagnosed myeloma patients treated with thalidomide-containing regimens: a randomized, controlled trial. Presented at: 13th European Hematology Association Annual Meeting. Copenhagen, Denmark, June 12–15 2008. Haematologica93(Suppl. 1) (2008) (Abstract 910).
   PubMedGoogle Scholar
• Mateos MV, Hernández JM, Hernández MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica93, 560–565 (2008).
   PubMed Web of Science ®Google Scholar
• Palumbo A, Falco P, Corradini P et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA – Italian Multiple Myeloma Network. J. Clin. Oncol.25, 4459–4465 (2007).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Jacobus S, Callander N et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8–11 December 2007. Blood110 (2007) (Abstract 74).
   PubMedGoogle Scholar
• Brinker BT, Waller EK, Leong T et al. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma. Cancer106, 2171–2180 (2006).
   PubMed Web of Science ®Google Scholar
• Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood108, 3289–3294 (2006).
   PubMed Web of Science ®Google Scholar
• Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum Phase II study. Br. J. Haematol.139, 429–433 (2007).
   PubMed Web of Science ®Google Scholar
• Ladetto M, Pagliano G, Avonto I et al. Consolidation with bortezomib, thalidomide and dexamethasone induces molecular remissions in autografted multiple myeloma patients. Presented at: 49th American Society of Hematology Annual Meeting. GA, USA, 8–11 December 2007. Blood110 (2007) (Abstract 530).
   Google Scholar
• Abdelkefi A, Ladeb S, Torjman L et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. Blood111, 1805–1810 (2008).
   PubMed Web of Science ®Google Scholar
• Barlogie B, Shaughnessy JD Jr, Crowley J. Duration of survival in patients with myeloma treated with thalidomide. N. Engl. J. Med.359, 210–212 (2008).
   PubMed Web of Science ®Google Scholar
• Barlogie B, van Rhee F, Shaughnessy JD Jr et al. Seven year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood (2008) (Epub ahead of print).
   Google Scholar
• Morgan GJ, Davies FE, Owen RG et al. Thalidomide combinations improve response rates; results from the MRC IX study. Blood110 (2007) (Abstract 3593).
   Google Scholar